Logo Image
News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeMedcastPeers & PerspectivesRoundtable DiscussionsShortsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesParkinsonism Practical GuideSponsoredThe G.L.O.B.Virtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
    • Huntington Disease
  • Neuro-Oncology
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
CMSC 2026|
ATMRD 2026|
AAIC 2026|
Parkinsonism Practical Guide
Advertisement

Mary Curry, ND

Advertisement

Articles by Mary Curry, ND

Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers

ByMary Curry, ND,Lisa Belter, MPH,Abigail Paras, BS,Leslie Humbel, BA,Jill Jarecki, PhD,Mary Schroth, MD, FAAP, FCCP
August 13th 2020

Advocacy organization Cure SMA provides guidance for health care providers caring for patients with SMA during the ongoing COVID-19 pandemic.

Advertisement

Latest Updated Articles

  • Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers
    Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers

    August 13th 2020



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

Phase 2 APPLAUDS Trial to Test Mivelsiran in Down Syndrome-Associated Alzheimer Disease

2

FDA Accepts NDA for Apnimed’s AD109 for the Treatment of Obstructive Sleep Apnea

3

Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3

4

FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment

5

Mitophagy Activator Urolithin A Enters Phase 2 Alzheimer Trial of APOE4 Carriers

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us